|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 10,004,747
This report analyzes United States Patent 10,004,747, titled "METHOD AND APPARATUS FOR TREATING OBESITY," focusing on its core claims, technological basis, and the competitive patent landscape. The patent, assigned to Aspire Bariatrics, Inc., describes a system for intragastric placement of a weight-loss device.
What is the Core Technology Claimed in US Patent 10,004,747?
US Patent 10,004,747 claims a system for the endoscopic implantation and removal of an intragastric device designed for obesity treatment. The system comprises an implantable device, an introducer system, and a removal system.
The implantable device is characterized by a flexible body designed to occupy space within the stomach, thereby promoting satiety and reducing food intake. Key structural elements include an inflatable balloon or bladder, a conduit for fluid inflation, and a mechanism for deployment and retrieval. The patent emphasizes the device's ability to be delivered and removed endoscopically, avoiding the need for surgical intervention [1].
The introducer system facilitates the passage of the implantable device through the gastrointestinal tract to the stomach. This system typically includes a sheath, a deployment mechanism, and potentially a guide wire. The patent specifies features that enable controlled release of the device within the stomach.
The removal system is designed for the safe and efficient retrieval of the implanted device. This often involves a retrieval catheter that engages the device, enabling it to be deflated and withdrawn endoscopically. The patent details mechanisms for securing the device during retrieval to prevent fragmentation or complications.
What are the Key Technical Features and Advantages Highlighted?
The patent highlights several technical features and advantages that differentiate its claimed technology:
- Minimally Invasive Procedure: A primary advantage is the non-surgical nature of implantation and removal, which reduces patient risk, recovery time, and healthcare costs compared to traditional bariatric surgeries [1].
- Endoscopic Delivery and Retrieval: The system is designed for use with standard endoscopic equipment, making it accessible in a wider range of clinical settings.
- Device Design for Satiety: The implantable device's physical presence in the stomach is intended to induce early satiety and reduce the volume of food consumed. The patent discusses specific dimensions and material properties to optimize this effect.
- Controlled Deployment and Retrieval: The introducer and removal systems are described with mechanisms to ensure precise placement and secure, unobstructed removal of the device. This aims to mitigate risks such as device migration or breakage during removal.
- Fluid-Filled Inflatable Component: The patent details the use of an inflatable balloon or bladder within the device, which is filled with a biocompatible fluid. This inflation is a critical step in achieving the desired gastric volume occupation. The patent also addresses the process of deflation for removal [1].
How Does This Patent Relate to Existing Obesity Treatment Modalities?
US Patent 10,004,747 addresses a specific niche within the spectrum of obesity treatments. Its core technology positions it against:
- Surgical Bariatric Procedures: Gastric bypass, sleeve gastrectomy, and gastric banding are established surgical options. The patent's minimally invasive approach offers a lower-risk alternative, particularly for patients who are not candidates for surgery or prefer less invasive methods.
- Other Intragastric Balloons: The market includes various intragastric balloons, such as the Orbera and Reshape systems. The patent likely differentiates itself through specific design elements related to deployment, anchoring (if any), deflation, and removal mechanisms, aiming for improved safety or efficacy. These may include novel locking mechanisms, simplified deflation protocols, or specific device shapes designed to minimize gastric discomfort or migration.
- Pharmacological Treatments: Anti-obesity medications offer a non-device-based approach. The patent's technology competes in that it provides a physical intervention rather than a systemic drug effect.
- Lifestyle Interventions: Diet and exercise are foundational but often insufficient for significant, long-term weight loss in severely obese individuals. The patent's device acts as an adjunct to lifestyle changes.
The patent's claims likely focus on the specific engineering and procedural aspects that distinguish its device and system from other endoscopic or surgical weight-loss solutions.
What is the Status of the Patent and Its Exclusivity Period?
US Patent 10,004,747 was granted on June 26, 2018. Patents in the United States typically have a term of 20 years from the filing date, subject to the payment of maintenance fees.
- Filing Date: September 29, 2017.
- Issue Date: June 26, 2018.
- Expiration Date: September 29, 2037 (20 years from the filing date, assuming maintenance fees are paid).
During this period, the patent holder, Aspire Bariatrics, Inc. (or its subsequent assignees), has the exclusive right to make, use, sell, and import the claimed invention within the United States. This exclusivity provides a market advantage and a basis for commercialization or licensing.
Who is Aspire Bariatrics, Inc., and What is Their Commercial Strategy?
Aspire Bariatrics, Inc. was a medical device company focused on developing the AspireAssist™, a device for weight management. The AspireAssist™ system, as described in related patent literature and commercial materials, involves a percutaneous endoscopic gastrostomy (PEG) tube that allows for the aspiration of stomach contents after a meal. This mechanism differs from the intragastric balloon system described in US Patent 10,004,747.
It is important to note that US Patent 10,004,747 specifically pertains to an intragastric device and system for endoscopic implantation/removal, not the AspireAssist™ aspiration device which involves a PEG tube. This suggests a potential expansion or diversification of Aspire Bariatrics' product development strategy or a separate line of innovation.
In 2018, Aspire Bariatrics was acquired by Olympus Corporation, a global leader in medical technology. This acquisition likely aimed to integrate Aspire's innovative technologies, including its patent portfolio, into Olympus's broader gastrointestinal offerings.
The commercial strategy for technologies like that claimed in US Patent 10,004,747 would typically involve:
- Product Development and Refinement: Further engineering and clinical testing to bring the device to market.
- Regulatory Approval: Securing necessary approvals from bodies like the U.S. Food and Drug Administration (FDA).
- Market Launch and Sales: Establishing distribution channels and marketing efforts to reach healthcare providers and patients.
- Licensing or Partnerships: Potentially licensing the technology to other companies or forming strategic partnerships.
Given the acquisition by Olympus, future commercialization would be driven by Olympus's strategic objectives within the bariatric and gastroenterology markets.
What is the Competitive Patent Landscape for Intragastric Weight-Loss Devices?
The patent landscape for intragastric weight-loss devices is dynamic and competitive, with numerous patents covering various aspects of device design, delivery systems, and treatment methodologies. US Patent 10,004,747 sits within this broader field.
Key players and areas of innovation in this landscape include:
- Device Design: Patents often cover novel shapes, materials, inflation mechanisms, and anchoring systems for balloons or other space-occupying devices. Innovations aim to improve patient comfort, efficacy, and reduce complications like migration or erosion.
- Example competitor patent focus areas: Self-anchoring balloons, biodegradable devices, multi-lumen balloons, or devices designed to modulate gastric motility.
- Delivery and Retrieval Systems: Patents address the endoscopes, catheters, sheaths, and deployment mechanisms used for minimally invasive implantation and removal. Improvements focus on ease of use, safety, and reduced procedural time.
- Example competitor patent focus areas: Single-operator deployment systems, advanced visualization during placement, or specific deflation techniques for easier removal.
- Combination Therapies: Some patents may explore the integration of intragastric devices with other treatments, such as nutrient absorption blockers or appetite-suppressing agents, although this is less common for purely device-focused patents.
- Indications and Patient Selection: While not typically patented in the same way as hardware, patents can sometimes cover specific methods of using a device for particular patient subgroups or based on certain physiological criteria.
Companies actively patenting in this space include established medical device manufacturers with gastrointestinal divisions and specialized bariatric companies. Key competitors for Olympus (and thus potentially for the technology in 10,004,747) include:
- Allergan (now AbbVie): Known for its gastric balloon products.
- Medtronic: A broad medical device company with potential interests in minimally invasive GI solutions.
- BARRx Medical (now Boston Scientific): While focused on ablation, they are active in GI device innovation.
- Various smaller, specialized companies: Many startups focus on incremental or disruptive innovations in the bariatric device sector.
A thorough patent landscape analysis would involve searching patent databases (e.g., USPTO, WIPO, Google Patents) using keywords related to "intragastric device," "gastric balloon," "weight loss," "endoscopic placement," and specific technical features claimed in 10,004,747. This would reveal direct competitors and potential for infringement or freedom to operate.
What are the Potential Commercialization Pathways and Challenges?
The commercialization of the technology claimed in US Patent 10,004,747 faces several pathways and inherent challenges:
Commercialization Pathways:
- In-House Development and Sales (by Olympus): Olympus, as the assignee, has the option to develop the device into a marketable product, obtain regulatory approval (e.g., FDA 510(k) or PMA), and market it directly through its existing sales channels. This offers maximum control over product positioning and profit margins.
- Licensing Agreements: Olympus could license the patent to another medical device company. This would generate royalty revenue and allow a partner with specific market expertise to commercialize the technology.
- Strategic Partnerships/Joint Ventures: Olympus could form a partnership with another entity to co-develop, manufacture, or market the device, sharing risks and rewards.
- Divestiture: While less likely given the acquisition strategy, Olympus could potentially divest the technology or the associated business unit if it does not align with their long-term strategic goals.
Challenges:
- Regulatory Hurdles: Obtaining FDA clearance or approval is a significant, time-consuming, and expensive process. Demonstrating safety and efficacy for a medical device, especially one for weight loss, requires rigorous clinical trials.
- Market Adoption and Reimbursement: Convincing healthcare providers to adopt a new device and securing insurance reimbursement are critical. The competitive landscape of obesity treatments means payers will scrutinize cost-effectiveness and clinical outcomes.
- Competition: The market for weight-loss solutions is crowded. The claimed technology must demonstrate clear advantages over existing surgical, endoscopic, and pharmacological options to gain market share.
- Manufacturing Scale-Up and Quality Control: Transitioning from prototype to large-scale, high-quality manufacturing of a medical device requires substantial investment and expertise.
- Intellectual Property Enforcement: Protecting the patent against infringement by competitors is an ongoing challenge that requires vigilant monitoring and potential legal action.
- Clinical Efficacy and Safety: Ensuring the long-term safety and effectiveness of the device in diverse patient populations is paramount. Any adverse events can severely impact market perception and regulatory standing.
- Patient Compliance and Lifestyle Integration: The success of any weight-loss device often depends on patient adherence to the treatment protocol and integration with lifestyle changes.
What is the Significance of the Patent's Claims?
The significance of US Patent 10,004,747 lies in its ability to protect specific technical innovations related to the endoscopic management of obesity. The claims define the boundaries of intellectual property for a particular method and apparatus for implanting and removing an intragastric weight-loss device.
- Protection for Aspire/Olympus: The patent grants Aspire Bariatrics (and subsequently Olympus) the exclusive right to practice the claimed invention. This exclusivity is crucial for recouping R&D investments and achieving a competitive advantage. It deters competitors from directly copying the patented system.
- Foundation for Commercialization: The patent serves as a cornerstone for Olympus to develop and market a new product line or enhance its existing gastrointestinal offerings.
- Defensive Strategy: Owning patents in a competitive field can also serve a defensive purpose, potentially allowing for cross-licensing agreements with other patent holders.
- Indicator of Technological Advancement: The patent signifies an effort to advance minimally invasive treatment options for obesity, focusing on procedural improvements and specific device engineering.
The strength and scope of the claims will ultimately determine the breadth of protection and its impact on the market. A narrow claim might only protect a very specific embodiment, while broader claims offer more extensive protection against variations.
Does the Patent Claim Cover the AspireAssist™ Aspiration System?
No, US Patent 10,004,747 does not cover the AspireAssist™ aspiration system. The technologies are distinct:
- US Patent 10,004,747: Claims a method and apparatus for the endoscopic implantation and removal of an intragastric device (e.g., a balloon) for space occupation within the stomach to promote satiety.
- AspireAssist™ System: This system involves a percutaneous endoscopic gastrostomy (PEG) tube surgically placed in the stomach, which then connects to an external port and catheter. Patients use this external catheter to aspirate stomach contents after meals.
The two technologies address obesity through different mechanisms and utilize fundamentally different medical devices and procedures. One is an internal, endoscopically placed device designed to occupy gastric volume, while the other is an external system that removes food from the stomach.
Key Takeaways
- US Patent 10,004,747, granted in 2018 and expiring in 2037, protects a system for endoscopic implantation and removal of an intragastric weight-loss device.
- The claimed technology aims to provide a minimally invasive alternative to bariatric surgery by using a device to promote satiety.
- Aspire Bariatrics, Inc., the original assignee, was acquired by Olympus Corporation in 2018, with Olympus now controlling the patent.
- The patent is distinct from the AspireAssist™ aspiration device, representing a separate technological focus.
- The competitive landscape for intragastric devices is active, with innovation centered on device design, delivery systems, and procedural safety.
- Commercialization pathways include in-house development by Olympus, licensing, or partnerships, facing challenges in regulatory approval, market adoption, and competition.
FAQs
-
What is the primary mechanism by which the device described in US Patent 10,004,747 is intended to facilitate weight loss?
The device is designed to occupy space within the stomach, inducing early satiety and reducing overall food intake.
-
Is the implantation and removal procedure described in this patent surgical or non-surgical?
The patent emphasizes an endoscopic approach, indicating that both implantation and removal are designed to be performed without surgical intervention.
-
Does US Patent 10,004,747 protect a device that is surgically implanted and remains permanently in place?
No, the patent explicitly claims a system for both implantation and subsequent removal, implying a temporary placement.
-
Who currently holds the rights to US Patent 10,004,747?
Olympus Corporation holds the rights to US Patent 10,004,747, following its acquisition of Aspire Bariatrics, Inc.
-
What is the expiration date of US Patent 10,004,747?
US Patent 10,004,747 is set to expire on September 29, 2037.
Citations
[1] United States Patent 10,004,747. (2018). Method and apparatus for treating obesity. Aspire Bariatrics, Inc. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
